Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458820 | 1.00 | BACE1 (0.41) | BACE1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL6802909 | 0.96 | ADRB3 (0.39) | BACE1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL6802914 | 0.96 | ADRB3 (0.39) | BACE1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL4462311 | 0.92 | BACE1 (0.42) | BACE1ADRB3ADRB1 | |
| SCHEMBL4462309 | 0.92 | BACE1 (0.42) | BACE1ADRB3ADRB1 | |
| SCHEMBL4468558 | 0.91 | BACE1 (0.39) | BACE1ADRB3ADRB1 | |
| SCHEMBL4468553 | 0.91 | BACE1 (0.39) | BACE1ADRB3ADRB1 | |
| SCHEMBL4472271 | 0.90 | ADRB3 (0.41) | BACE1ADRB3 | |
| SCHEMBL4472266 | 0.90 | ADRB3 (0.41) | BACE1ADRB3 | |
| SCHEMBL4468717 | 0.88 | ALDH1A1 (0.45) | BACE1ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | BACE1 3315/4885ADRB3 130/4885ADRB1 39/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | BACE1 3808/4885ADRB3 568/4885ADRB1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.